SOURCE: Health Enhancement Products, Inc.

September 24, 2007 08:30 ET

Health Enhancement Products Announces the Signing of a Broker Agreement With Natural Brokers, Inc.

SCOTTSDALE, AZ--(Marketwire - September 24, 2007) - Health Enhancement Products, Inc. (OTCBB: HEPI) (the "Company") announced today that it had signed an agreement with Natural Brokers, Inc., of Phoenix, Arizona, to represent ProAlgaZyme in a five state territory, including Arizona, Nevada, New Mexico, Colorado and Utah.

Natural Brokers, along with Rich Hellyer (the company's new marketing consultant), will attend the upcoming Expo East show in Baltimore Maryland September 26-29th, introducing HEPI's primary product, ProAlgaZyme, to an estimated 10,000 qualified buyers attending the convention. Expo East is the largest natural products showcase on the East Coast with attendees representing the largest supermarkets and heath food chains in the country.

Natural Brokers is the first brokerage firm signed up to assist Health Enhancement in its long awaited national roll out. It is anticipated that other brokerage firms will be signed up in the near future.

About Natural Brokers, Inc.

Natural Brokers, Inc. was founded in 1984 and is the manufacturer's Sales Representative for many name brand natural products. Natural Brokers, Inc. sells to Wild Oats, Whole Foods, Vitamin Cottages, Sunflower Markets, Sprouts, Hi-Health, Arizona Health Food Stores and many others.

About Health Enhancement Products, Inc. and ProAlgaZyme®

Health Enhancement Products, Inc. is a nutraceutical company engaged in the development of a Dietary Supplement product using only pure, all-natural ingredients. The company's sole product is ProAlgaZyme®, a liquid product produced from algae grown in 100% distilled water. The liquid in which the algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme®. ProAlgaZyme®, currently available on the internet as a nutraceutical product at www.heponline.com, is known to have been used in humans since the 1980s. Since that time, clinical trials have been completed in lab animals as well as humans, with encouraging results.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, our inability to obtain regulatory approvals necessary to market and sell PAZ as a pharmaceutical, and the company's ability to secure funding, including for the subsidiary's pharmaceutical development of PAZ. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit www.heponline.com.

Contact Information